Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer

被引：4
|
作者：
Guarducci, Cristina
Cristea, Simona
Feit, Avery
Naumenko, Sergey
Nardone, Agostina
Ma, Wen
Russo, Douglas
Feit, Gabriella Cohen
Feiglin, Ariel
Hermida-Prado, Francisco
Sherman, Shira
Brown, Myles
Michor, Franziska
Jeselsohn, Rinath
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-GS3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer
    Li, Qing
    Razavi, Pedram
    Li, Zhiqiang
    Paula, Arnaud F. Da Cruz
    Brogi, Edi
    Scaltriti, Maurizio
    Reis-Filho, Jorge S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2019, 79 (13)
  • [42] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [43] Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Li, Zhen
    Zou, Wei
    Zhang, Ji
    Zhang, Yunjiao
    Xu, Qi
    Li, Siyuan
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [44] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
    Owsley, J.
    Jimeno, A.
    Diamond, J. R.
    DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
  • [45] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [46] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Targeting 6-phosphofructo-2-kinase to increase the efficacy of ER and CDK4/6 inhibitors against breast cancer
    Imbert-Fernandez, Yoannis
    Lanceta, Lilibeth
    Telang, Sucheta
    Chesney, Jason
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Unravelling mechanisms of resistance to CDK4/6 inhibitors using triple negative breast cancer (TNBC)
    Asghar, U.
    Barr, A.
    Cutts, R.
    Beaney, M.
    Sampath, D.
    Giltnane, J.
    Lacap, J. Arca
    Herrera-Abreu, M.
    Bakal, C.
    Turner, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Development of personalized medicine for breast cancer based on elucidation of resistance mechanisms to CDK4/6 inhibitors
    Kobayashi, Yoshie
    Motoi, Yusuke
    Fujimoto, Mutsumi
    Shigematsu, Hideo
    CANCER RESEARCH, 2023, 83 (05)
  • [50] The Role of CDK4/6 Inhibitors in Breast Cancer
    Murphy, Conleth G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
12345